BE2017C021I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C021I2
BE2017C021I2 BE2017C021C BE2017C021C BE2017C021I2 BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2 BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2
Authority
BE
Belgium
Application number
BE2017C021C
Other languages
Dutch (nl)
Original Assignee
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Bioscience Co Ltd filed Critical Sk Bioscience Co Ltd
Publication of BE2017C021I2 publication Critical patent/BE2017C021I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2017C021C 2003-01-28 2017-06-19 BE2017C021I2 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide

Publications (1)

Publication Number Publication Date
BE2017C021I2 true BE2017C021I2 (OSRAM) 2023-03-07

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C021C BE2017C021I2 (OSRAM) 2003-01-28 2017-06-19

Country Status (13)

Country Link
US (1) US7041635B2 (OSRAM)
EP (2) EP1587832B1 (OSRAM)
KR (1) KR100642293B1 (OSRAM)
CN (1) CN100404552C (OSRAM)
AU (1) AU2003274766B8 (OSRAM)
BE (1) BE2017C021I2 (OSRAM)
CA (1) CA2514646C (OSRAM)
DK (2) DK1587832T3 (OSRAM)
ES (1) ES2446041T3 (OSRAM)
FR (1) FR17C1024I2 (OSRAM)
LU (1) LUC00023I2 (OSRAM)
NL (1) NL300878I2 (OSRAM)
WO (1) WO2004067566A1 (OSRAM)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CA2604299A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR101389376B1 (ko) 2007-02-23 2014-04-29 에스케이케미칼주식회사 제 ８ 인자 및 그의 유도체의 제조 및 정제 방법
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
JP5619630B2 (ja) 2008-02-27 2014-11-05 ノボ・ノルデイスク・エー／エス 結合型第ｖｉｉｉ因子分子
US20110077202A1 (en) * 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
ES2730800T3 (es) 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
WO2012061689A2 (en) * 2010-11-05 2012-05-10 Ipsen Pharma S.A.S. A new variant of antihemophilic factor viii having increased specific activity
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
JP2014531910A (ja) 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
JP6072810B2 (ja) 2011-10-18 2017-02-01 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用
ES2753124T3 (es) 2012-01-12 2020-04-07 Bioverativ Therapeutics Inc Polipéptidos quiméricos de factor VIII y usos de los mismos
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
DK2814840T3 (da) 2012-02-15 2020-02-03 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
HK1207591A1 (en) 2012-06-08 2016-02-05 Biogen Ma Inc. Chimeric clotting factors
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CA2935954A1 (en) 2014-01-10 2015-07-16 Biogen Ma Inc. Factor viii chimeric proteins and uses thereof
US10822393B2 (en) * 2014-01-20 2020-11-03 Octapharma Ag Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
SG10201900598TA (en) 2014-08-04 2019-02-27 Csl Ltd Factor viii formulation
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
MX2017014872A (es) 2015-05-22 2018-07-06 Csl Behring Recombinant Facility Ag Metodos para preparar factor de von willebrand modificado.
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
MY205187A (en) 2015-11-13 2024-10-04 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
NZ745831A (en) 2016-02-01 2025-07-25 Bioverativ Therapeutics Inc Optimized factor viii genes
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
EP3476860A4 (en) 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
KR20240069834A (ko) 2016-12-02 2024-05-20 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110799208A (zh) 2017-06-22 2020-02-14 康诺贝林伦瑙有限公司 截短的vwf对fviii免疫原性的调节
US12168776B2 (en) 2017-08-09 2024-12-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
WO2020061281A1 (en) * 2018-09-19 2020-03-26 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020168362A1 (en) * 2019-02-15 2020-08-20 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
EP3938741B1 (en) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilization container fill fixture, system and method of use
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP7681268B2 (ja) * 2020-03-30 2025-05-22 シスメックス株式会社 血液凝固活性の測定方法
TW202208619A (zh) 2020-06-24 2022-03-01 美商百歐維拉提夫治療公司 用於純化病毒載體之方法
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
MX2024003963A (es) 2021-09-30 2024-04-29 Bioverativ Therapeutics Inc Acidos nucleicos que codifican polipeptidos factor viii con inmunogenia reducida.
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
DK1754718T3 (da) * 1996-04-24 2011-07-18 Univ Michigan Inaktiveringsresistent faktor VIII
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
US20040192599A1 (en) 2001-06-15 2004-09-30 Schuh Andre C Gene therapy for hemophilia a

Also Published As

Publication number Publication date
ES2446041T3 (es) 2014-03-06
WO2004067566A1 (en) 2004-08-12
EP2253645B1 (en) 2016-03-23
NL300878I2 (nl) 2017-11-02
LUC00023I1 (OSRAM) 2017-06-21
AU2003274766A1 (en) 2004-08-23
AU2003274766B8 (en) 2009-08-27
CA2514646A1 (en) 2004-08-12
HK1150840A1 (en) 2012-01-13
US20040147436A1 (en) 2004-07-29
DK1587832T3 (en) 2014-02-24
EP1587832B1 (en) 2013-12-11
CA2514646C (en) 2013-07-23
FR17C1024I2 (fr) 2019-07-19
AU2003274766B2 (en) 2009-02-12
KR100642293B1 (ko) 2006-11-03
LUC00023I2 (OSRAM) 2017-09-08
FR17C1024I1 (OSRAM) 2017-09-08
EP2253645A3 (en) 2011-02-16
DK2253645T3 (en) 2016-06-27
CN1745100A (zh) 2006-03-08
US7041635B2 (en) 2006-05-09
EP2253645A2 (en) 2010-11-24
CN100404552C (zh) 2008-07-23
KR20050044776A (ko) 2005-05-12
EP1587832A1 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
LUC00023I2 (OSRAM)
BE2013C075I2 (OSRAM)
BE2013C069I2 (OSRAM)
BE2013C067I2 (OSRAM)
BE2013C038I2 (OSRAM)
BE2013C036I2 (OSRAM)
BE2011C030I2 (OSRAM)
BE2013C034I2 (OSRAM)
BE2012C053I2 (OSRAM)
JP2003299632A5 (OSRAM)
JP2003297751A5 (OSRAM)
AU2002331433A1 (OSRAM)
AU2002345911A1 (OSRAM)
AU2002316235A1 (OSRAM)
AU2002316511A1 (OSRAM)
AU2002318342A1 (OSRAM)
AU2002321535A1 (OSRAM)
AU2002322913A1 (OSRAM)
AU2002324323A1 (OSRAM)
AU2002327042A1 (OSRAM)
AU2002327736A1 (OSRAM)
AU2002329412A1 (OSRAM)
AU2002310561A1 (OSRAM)
AU2002332887A1 (OSRAM)
AU2002333044A1 (OSRAM)